Tillotts Pharma Ag

Tillotts Pharma Ag logo
🇸🇪Sweden
Ownership
Subsidiary
Established
1986-01-01
Employees
501
Market Cap
-
Website
http://www.tillotts.com
Clinical Trials
Related News

Pharmaco-Scintigraphic Study to Evaluate the Release Profile of Metronidazole Benzoate Capsules

First Posted Date
2016-09-22
Last Posted Date
2017-04-04
Lead Sponsor
Tillotts Pharma AG
Target Recruit Count
18
Registration Number
NCT02911298
Locations
🇨🇭

University Hospital Basel, Phase I Research Unit, Basel, Basel-Stadt, Switzerland

TP0502-B-Pharmaco-Scintigraphic-Study

Phase 1
Completed
Conditions
Ulcerative Colitis
Interventions
Drug: TP05
First Posted Date
2014-12-03
Last Posted Date
2014-12-04
Lead Sponsor
Tillotts Pharma AG
Target Recruit Count
9
Registration Number
NCT02306798

TP0501 - Pharmaco-Scintigraphic-Study

Phase 1
Completed
Conditions
Ulcerative Colitis
Interventions
Drug: TP05 Coating A
Drug: TP05 Coating B
First Posted Date
2014-12-03
Last Posted Date
2014-12-03
Lead Sponsor
Tillotts Pharma AG
Target Recruit Count
18
Registration Number
NCT02306772

TP0502-Pharmaco-Scintigraphic-Study and Amendment

First Posted Date
2014-12-03
Last Posted Date
2014-12-03
Lead Sponsor
Tillotts Pharma AG
Target Recruit Count
26
Registration Number
NCT02306785

TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)

Phase 3
Completed
Conditions
Acute Ulcerative Colitis
Interventions
Drug: TP05
Drug: Asacol 400 mg
First Posted Date
2013-07-19
Last Posted Date
2018-08-08
Lead Sponsor
Tillotts Pharma AG
Target Recruit Count
817
Registration Number
NCT01903252
Locations
🇨🇭

Tillotts Pharma AG, Rheinfelden, Baslerstrasse 15, Switzerland

Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase

First Posted Date
2010-12-09
Last Posted Date
2013-04-04
Lead Sponsor
Tillotts Pharma AG
Target Recruit Count
251
Registration Number
NCT01257399
Locations
🇨🇳

Shanghai Hospital, Shanghai, China

Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis

Phase 3
Completed
Conditions
Active Ulcerative Colitis
Interventions
Drug: Asacol®
Drug: Mesalazine
First Posted Date
2010-12-09
Last Posted Date
2013-04-04
Lead Sponsor
Tillotts Pharma AG
Target Recruit Count
251
Registration Number
NCT01257386
Locations
🇨🇳

Shanghai Hospital, Shanghai, China

Efficacy and Safety of Asacolâ„¢ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis

Phase 3
Completed
Conditions
Ulcerative Colitis
Interventions
Drug: Mesalamin
First Posted Date
2010-01-29
Last Posted Date
2017-08-02
Lead Sponsor
Tillotts Pharma AG
Target Recruit Count
281
Registration Number
NCT01059344
Locations
🇹🇷

Gazi University Medical Faculty Besevler, Ankara, Turkey

🇹🇷

Gaziantep University Medical Faculty Kampus Alani, Gaziantep, Turkey

🇮🇳

Maulana Azad Medical College and Associated Lok Nayak Hospital, New Delhi, India

and more 28 locations

EPANOVA in Crohn's Disease, Study 1

Phase 3
Completed
Conditions
Crohn's Disease
Interventions
Drug: Epanova
First Posted Date
2008-02-12
Last Posted Date
2013-04-04
Lead Sponsor
Tillotts Pharma AG
Target Recruit Count
384
Registration Number
NCT00613197
Locations
🇧🇪

University of Leuven, Leuven, Belgium

An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanovaâ„¢) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease

Phase 3
Completed
Conditions
Crohn's Disease
First Posted Date
2003-12-16
Last Posted Date
2007-02-21
Lead Sponsor
Tillotts Pharma AG
Target Recruit Count
364
Registration Number
NCT00074542
Locations
🇺🇸

Atlanta Gastroenterology Associates, Atlanta, Georgia, United States

🇨🇦

St. Michael's Hospital, Toronto, Ontario, Canada

🇺🇸

Long Island Clinical Research Associates, Great Neck, New York, United States

and more 27 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy